Introduction
============

Cancer is the second leading cause of deaths worldwide [@B1]. Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death in men; colorectal cancer is the third most commonly diagnosed cancer in males and the second in females; gastric cancer is followed by a high incidence and mortality rates [@B1]; and pancreatic cancer is usually diagnosed at a late stage with high mortality worldwide with over 330,000 deaths annually [@B2]. The high mortality of cancers is partly ascribed to late diagnosis and poor prognosis [@B1]. Computer tomography and magnetic resonance imaging are reliable techniques commonly used to detect cancers. The former poses uncertain risk to patients with poor specificity despite its high sensitivity [@B3] and the latter is not suitable for some patients with metallic foreign-body, such as cardiac pacemaker. Currently, many commonly used serum tumor markers usually limit to late stage with low sensitivity and specificity [@B4], [@B5]. General approaches to screening cancer and early diagnosis remain challenges. Therefore, it is necessary to find timely and accurately methods for early differentiation of pathophysiological states.

Phospholipids, as one of the major components of cell membrane, participate in various biological functions [@B6], and alter in various human cancers [@B7]-[@B10]. Sphingomyelins (SMs) are associated with membrane fluidity [@B11], and SMs and their metabolic products can regulate cancer cell apoptosis [@B12]. Phosphatidylcholines (PCs) are the most abundant bilayer-forming phospholipid of eukaryotic membranes [@B13], and it is found that PCs can contribute to proliferative growth in cancer cells [@B14] and that abnormal metabolism of SMs and PCs are also correlated with various cancers [@B15]-[@B19] as well as with gender [@B20].

Direct-infusion mass spectrometry can rapidly perform analysis of biological samples, while carryover effect in metabolites analysis has limited its application for biomarker discovery and clinical diagnostics. Recently, the TriVersa NanoMate^®^, a chip-based direct-infusion nanoelectrospray ionization (CBDInanoESI) technique coupled with a Fourier transform ion cyclotron resonance mass spectrometer (FTICR MS) has shown a comparative advantage of analysis of the targeted compounds in biological sample, along with short analytical time, low sample consumption, high sensitivity, and less carryover effects [@B21]-[@B24].

In this study, a high-throughput quantitative method of multiple targeted phospholipids (*i.e.*, SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2)) was developed based on the CBDInanoESI-FTICR MS. Their levels in 1449 serum samples from 599 normal controls, 251 patients with benign diseases (*i.e.*, lung, bowel, stomach, and pancreas), and 599 corresponding cancer patients were obtained on the basis of their respective calibration equations with correlation coefficient of \>0.98. The experimental results indicate that the levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) were associated with gender and different pathophysiological states. Receiver operating characteristic (ROC) analysis indicated that potential biomarker panels have high diagnostic ability to differentiate different pathophysiological states or cancer stages relative to clinical commonly used tumor markers.

Materials and methods
=====================

Chemicals
---------

Phospholipids (with purity of \> 99%) including N-palmitoyl-D-erythro-sphingosylphosphorylcholine (SM(34:1)), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (PC(34:1)), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (PC(34:2)), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (PC(36:4)) and 1,2-dielaidoyl-sn-glycero-3-phosphocholine (PC(36:2)) were purchased from Avanti Polar lipids (Alabaster, AL, USA). 1,2-diastearoyl-sn-glycero-3-phosphocholine (PC(36:0)) as internal standard was purchased from Sigma-Aldrich Chemicals (St. Louis, MO, USA). HPLC-grade dichloromethane, methanol, and acetonitrile were from Fisher Scientific (Fair Lawn, NJ, USA). Ultrapure water was purified by a Milli-Q system (Millipore, MA, USA).

Participants and study design
-----------------------------

All samples are remaining sera after the clinical laboratory examination which were drawn in the morning after about 10 hours overnight fast without bowel preparation, followed by less than three-year storage at -80℃ before analysis. A total of 1449 serum samples were collected, including 599 normal controls, with no clinically relevant abnormalities and 850 patients (246 patients with lung cancer, 144 with colorectal cancer, 94 with gastric cancer, 115 with pancreatic cancer, and 69 with benign lung diseases, 61 with benign colorectal diseases, 54 with benign gastric diseases, 67 with benign pancreatic diseases). The training set including 177 normal controls and 177 lung cancer patients was used to discover the difference in the levels of these six targeted phospholipids between gender, pathophysiological states, and cancer stages. The rest of the participants was classified as the different validation sets based on the types of diseases. Detailed information of the participants is shown in **Table [1](#T1){ref-type="table"}**. All experiments were performed in accordance with relevant guidelines and regulations, and the informed consent was obtained. The study was approved by the Ethics Review Board at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences.

Preparation of stock standard solutions
---------------------------------------

Stock solution of 10.75 μM SM(34:1), 29.96 μM PC(34:2), 29.88 μM PC(34:1), 29.04 μM PC(36:4), or 28.90 μM PC(36:2) was prepared in acetonitrile/methanol/water (3.6:5.4:1, v/v/v) with 10 mM ammonium acetate and the mixed stock standard solution was obtained by pooling the above-mentioned stock standard solutions at the ratio of 4:5:2:2.5:2.7 (v/v/v/v/v). The final concentrations of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) were 2.65 μM, 9.24 μM, 3.69 μM, 4.48 μM, and 4.81 μM, respectively.

Sample preparation
------------------

Serum sample was thawed at 4 °C, and then 50 μL of each sample was added to 950 μL of acetonitrile/methanol (3:2, v/v). The mixture was vortexed for 30 s and then stored at -20°C for 24 h. The supernatant was obtained after centrifugation separation at 15,000×*g* for 30 min and sequentially transferred into a new 1.5 mL tube and stored at -80 °C until use. 15 μL of the supernatant was spiked with 34 μL of the internal standard (3.17 μM PC(36:0)), and then 500 μL of dichloromethane and 200 μL of ultrapure water was added, followed by vortexing for 30 s. The mixture was centrifuged at 1,500×*g* for 10 min, and 100 μL of the organic phase was transferred into a new 1.5 mL tube. After the organic phase was dried at room temperature, the residue was redissolved in 1.5 mL of acetonitrile/methanol/water (3.6:5.4:1, v/v/v) with 10 mM ammonium acetate.

Mass spectrometry
-----------------

All experiments were performed on a 9.4 T apex-ultra™ hybrid Qh-FTICR MS (Bruker Daltonics, Billerica, MA) equipped with TriVersa NanoMate^®^electrospray ionization source (Advion BioSciences, Ithaca, NY, USA). The sample was introduced by TriVersa NanoMate^®^with 0.5 psi gas pressure, 1.6 kV voltage in positive ion mode. The parameters of FTICR MS were as follows: both of the capillary and spray shield voltages were 0 V, the drying gas temperature was 150 °C. Mass spectrum was accumulated by 10 full scans over the *m/z* range of 700-900 with 512 kilobytes per second acquisition size at a resolution of 450,000 at *m/z* 400.

Data handling and analysis
--------------------------

Mass spectral data were obtained using Apex Control 3.0.0 software (Bruker Daltonics, Billerica, MA). Peaks with signal-to-noise ratio, relative intensity, and absolute intensity thresholds of 5, 0.1%, and 10,000, respectively, were chosen as reliable metabolites. After isotopic deconvolution and normalization against the intensity of the internal standard, the levels of six targeted phospholipids were calculated based on the calibration equations and then analyzed by Mann-Whitney U test. Potential effects of age on different pathophysiological states were assessed by partial least squares-discriminant analysis. The ROC analysis was used to calculate AUC. A *p* value of \< 0.05 was considered as statistically significant. Statistical analyses were performed by SAS software (version 9.2, SAS Institute Inc.) and SPSS software (version 16.0, SPSS Inc.).

Structural identification of the targeted phospholipids
-------------------------------------------------------

The identification of the targeted phospholipids was performed as described previously [@B20]. Briefly, the identification was based on the observed accurate molecular mass, isotope distribution, tandem mass spectra, and the comparison of tandem mass spectra of their corresponding standard compounds. The mass error was less than 0.0015 Da and the relative error of their isotopic intensities relative to their theoretical values was less than 5%. The collision-induced dissociation experiments were chosen to get tandem mass spectra of the targeted phospholipids.

Method validation for quantitative analysis
-------------------------------------------

The reliability of the CBDInanoESI-FTICR MS platform for the quantification of these six phospholipids was validated through their linearity, limitation of detection (LOD), limitation of quantitation (LOQ), precision, stability, and spike-and-recovery.

To construct the calibration curves of each phospholipids, the mixed stock standard solution was diluted by the acetonitrile/methanol/water (3.6:5.4:1, v/v/v) with 10 mM ammonium acetate to 2^4^, 2^5^, 2^7^, 2^8^, 2^9^, 2^10^, 2^11^, 2^12^, 2^13^ and 2^14^ fold, respectively. And then 1200 μL of each of the resulting standard solutions was mixed with 10 μL of the internal standard as working solution (the final concentration of internal standard was 13.17 nM). Six runs for each of the working solutions were performed by the CBDInanoESI-FTICR MS. The calibration curves were generated between the concentration ratios of each phospholipids to the internal standard and the intensity ratios of their corresponding phospholipids to the internal standard, respectively. In addition, the calibration curve of PC(36:2) was also used for quantifying PC(36:3) because its commercial standard was not available. Each of the abovementioned working solutions were analyzed three times and the results were shown as mean ± standard deviation.

The mixed stock standard solution was also diluted by acetonitrile/methanol/water (3.6:5.4:1, v/v/v) with 10 mM ammonium acetate to obtain LOD (S/N=3) and LOQ (S/N=10) of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2), respectively.

Quality control (QC) sample was prepared by mixing equal volume of 10 normal controls sera, 10 benign diseases patients sera, and 10 cancer patients sera. The experimental precision was assessed based on the intraday precision of three measured values of the QC sample on the same day and the interday precision of three measured values of the QC sample on nine consecutive days. The experimental stability was also investigated by analyzing QC sample once every 20 test samples, and a total of 73 QC spectra were obtained in this study.

To assess the effect of different matrixes on the efficiency and recovery of phospholipids extraction, the spike-and-recovery experiment was performed based on serum matrix (termed as set 1) and the corresponding supernatant matrix (set 2), respectively. Three different concentration solutions of the mixture of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) in acetonitrile/methanol/water (3.6:5.4:1, v/v/v) with 10 mM ammonium acetate were prepared as below: R1: 106.75 μM SM(34:1), 231.00 μM PC(34:2), 98.74 μM PC(34:1), 95.96 μM PC(36:4), and 95.47 μM PC(36:2); R2: 35.58 μM SM(34:1), 99.00 μM PC(34:2), 65.83 μM PC(34:1), 63.97 μM PC(36:4), and 63.65 μM PC(36:2); R3:~.~ 5.34 μM SM(34:1), 33.00 μM PC(34:2), 32.91 μM PC(34:1), 31.99 μM PC(36:4), 31.82 μM PC(36:2). For the set 1, three equal volumes (each 50 μL of the diluted serum by addition of 40 μL water) of serum were mixed with 760 μL of the above-mentioned three different concentration solutions, respectively. The resulting mixtures were further mixed with 190 μL of acetonitrile/methanol (3:2, v/v) to precipitate serum proteins, respectively. The extraction process of phospholipids was performed based on the process in the section of sample preparation. For the set 2, the protein precipitant of 50 μL of the diluted serum by addition of 40 μL water was performed based on the process in section of sample preparation. And then 3 μL of the supernatant was mixed with 12 μL of the above mentioned three different concentrations, respectively, and the resulting solutions were termed as "new supernatants". The phospholipids extraction of these "new supernatants" was performed as described in the section of sample preparation. These samples were analyzed by the CBDInanoESI-FTICR MS, and their levels were calculated based on their corresponding calibration equations.

Results
=======

Quantitative method for measuring serum levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2)
------------------------------------------------------------------------------------------------------

Five calibration equations of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) were established based on the CBDInanoESI-FTICR MS, along with correlation coefficients of \> 0.98 and linearity ranges of around three orders of magnitude (**Table [2](#T2){ref-type="table"}**). The LOD and the LOQ of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) ranged from 0.06 to 0.16 nM and from 0.45 to 1.16 nM, respectively. Both of the relative standard deviations (RSDs) of intraday and interday precision were \< 17% (**Table [2](#T2){ref-type="table"}**). In addition, the recoveries of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) in serum matrix (set 1) and the corresponding supernatant matrix (set 2) were from 62% to 109% and from 63% to 112%, respectively, along with their RSD% of less than 13% (**Table [3](#T3){ref-type="table"}**), indicating that the detected levels in between the supernatant and serum were almost identical. Therefore, for the following experiments, the levels of these targeted phospholipids in the supernatant were determined. The RSD% of the QC sample indicated that the stability and reliability (RSD% \< 20%) of the CBDInanoESI-FTICR MS platform were acceptable for complex biological sample analysis (**Table [S1](#SM1){ref-type="supplementary-material"}**).

Simultaneous quantification of the targeted phospholipids
---------------------------------------------------------

In this study, SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in serum samples from 599 normal controls, 251 patients with benign diseases (including lung, bowel, stomach, and pancreas) and 599 corresponding cancer patients were simultaneously detected using the CBDInanoESI-FTICR MS platform (**Table [1](#T1){ref-type="table"}**). Their representative mass spectra from the participants with different pathophysiological states are shown in**Figure [1](#F1){ref-type="fig"}**. These targeted phospholipids were also confirmed on the basis of their observed masses with mass error of \<0.0015 Da relative to their respective theoretical masses and their detected isotope distributions with the RSD% of \< 5% relative to their respective theoretical distributions (**Table [S2](#SM1){ref-type="supplementary-material"}**). The levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) were calculated based on their respective calibration equations (**Table [2](#T2){ref-type="table"})**, and PC(36:3) was calculated based on the calibration equation of PC(36:2). Their levels of the age-matched participants classified by gender are shown in **Figures [2](#F2){ref-type="fig"}-[5](#F5){ref-type="fig"}**.

Association of the levels of these targeted phospholipids with pathophysiological states
----------------------------------------------------------------------------------------

For lung diseases, in the training set study, the levels of SM(34:1), PC(34:2), and PC(34:1) in both male and female lung cancer patients were significantly increased and PC(36:3) and PC(36:2) in male patients with lung cancer were only significantly increased relative to the normal controls with corresponding gender (**Figure [2](#F2){ref-type="fig"}**). In the validation set study, as shown in **Figure [2](#F2){ref-type="fig"}**, the levels of PC(36:4), PC(36:3), and PC(36:2) in both male and female with benign lung diseases were significantly decreased, and increased SM(34:1) and PC(34:1) in females with benign lung diseases and decreased PC(34:2) in male benign lung diseases were observed relative to the normal controls with corresponding gender. The levels of PC(34:2), PC(34:1), PC(36:3), and PC(36:2) in both males and females with lung cancer were remarkably increased compared with the corresponding benign lung diseases patients, while SM(34:1) was only significantly increased in male with lung cancer relative to male with benign lung diseases.

For colorectal diseases, change trends of these targeted phospholipids in colorectal diseases are shown in **Figure [3](#F3){ref-type="fig"}**. It was found that the levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), and PC(36:2) in both males and females with colorectal cancer were significantly increased compared with the benign colorectal diseases or normal controls with the corresponding gender, except for PC(36:4) in male colorectal cancer and PC(36:3) in both females with benign colorectal diseases and females with colorectal cancer. In addition, significant increase in the levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in both males and females with colorectal cancer were detected relative to the benign colorectal diseases with corresponding gender, except for PC(36:4) in males and PC(36:3) in females. It should be noted that increased levels of PC(34:1) and PC(36:4) in both males and females with benign colorectal diseases were observed compared with the controls with corresponding gender.

For gastric diseases, expression levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) were closely associated with pathophysiological states (**Figure [4](#F4){ref-type="fig"}**). For male and female groups, significantly increased levels of these six phospholipids in patients with gastric cancer were observed relative to the controls with corresponding gender and benign gastric diseases with corresponding gender (**Figure [4](#F4){ref-type="fig"}**). It is worth noting that remarkable differences in their levels between gastric cancer and benign gastric diseases for each gender group were also detected. In addition, expression levels of PC(34:2), PC(34:1), and PC(36:4) could also reflect the differences between controls and benign gastric diseases for both males and females, except for PC(36:4) in male group.

For pancreatic diseases, as shown in **Figure [5](#F5){ref-type="fig"}**, change trends of these six targeted phospholipids were different from the above mentioned diseases that originated from lung, stomach, and intestine. It is found that the level of PC(36:4) in both male and female patients with pancreatic cancer were significantly decreased compared with the controls with corresponding gender and the female patients with benign pancreatic diseases. In addition, for the female group, significantly decreased levels of SM(34:1), PC(34:2), PC(36:3) and PC(36:2) were detected relative to the corresponding controls and/or benign pancreatic diseases (**Figure [5](#F5){ref-type="fig"}**).

Association of the levels of the targeted phospholipids with cancer stages
--------------------------------------------------------------------------

As shown in **Figure [2](#F2){ref-type="fig"}**, significant increase in the levels of SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in male patients with early stage or late stage lung cancer were observed compared with the controls plus benign lung diseases with corresponding gender, except for PC(36:4) in early stage. However, SM(34:1), PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in female patients with late stage lung cancer were only remarkably up-regulated relative to the female controls plus benign lung diseases, except for significant increase in the levels of SM(34:1) and PC(34:1) in early stage. As shown in **Figure [3](#F3){ref-type="fig"}**, significant increase in the levels of SM(34:1), PC(34:2), PC(34:1), PC(36:3), and PC(36:2) in both male and female patients with early stage or late stage colorectal cancer were observed relative to the controls plus benign colorectal diseases with corresponding gender, except for PC(36:3) in female group. For gastric cancer, gastric cancer stages are closely correlated with expression levels of these six phospholipids (**Figure [4](#F4){ref-type="fig"})**. SM(34:1), PC(34:2), PC(34:1) PC(36:4), PC(36:3), and PC(36:2) in males and females with early stage or late stage gastric cancer were significantly up-regulated relative to the controls plus benign gastric diseases with corresponding gender, except for PC(36:4), PC(36:3), and PC(36:2) in male early stage and PC(36:2) in female late stage. It should be noted that significant decrease in the levels of PC(34:2) and PC(36:4) in females with later stage gastric cancer and significant increase in the level of PC(36:3) in males with later stage gastric cancer were observed compared with the corresponding gender patients with early stage gastric cancer. As shown in **Figure [5](#F5){ref-type="fig"}**, for males with pancreatic diseases, increased PC(34:1) and decreased PC(36:4) in patients with late stage pancreatic cancer were remarkably observed relative to controls plus benign pancreatic diseases. For females with pancreatic diseases, decreased SM(34:1), PC(34:2), PC(36:4), PC(36:3), and PC(36:2) in late stage pancreatic cancer were detected compared with controls plus benign pancreatic diseases.

Diagnostic ability
------------------

To estimate the diagnostic ability of these six targeted phospholipids, ROC analysis was further performed. Finally, 18 of panels (*i.e.*, panels a -r) are listed in **Figure [6](#F6){ref-type="fig"}**. It is found that panels a-k have good diagnostic ability to differentiate different pathophysiological states (**Table [4](#T4){ref-type="table"} and Figure [7](#F7){ref-type="fig"}**). For example, panel a has the AUC value of \>0.91, the sensitivity of \>83%, and the specificity of 83% to differentiate male controls from male lung cancer, panel b has the AUC value of \>0.93, the sensitivity of \>83%, and the specificity of 96% to differentiate female controls from female lung cancer, panel e has the AUC value of 0.929, the sensitivity of 81.5%, and the specificity of 96.3% to differentiate male benign lung diseases from male lung cancer, and panel f has the AUC value of 0.833, the sensitivity of 81.0%, and the specificity of 71.4% to differentiate female benign lung diseases from female lung cancer. Representative ROC curves are shown in **Figure [8](#F8){ref-type="fig"}**.

As shown in **Figure [9](#F9){ref-type="fig"}**, panels a, b, d, e, h, i, l, m, n, o, p, q, and r have good performance to perform early diagnosis for four types of cancer, and the details of their diagnostic performance are listed in **Table [5](#T5){ref-type="table"}**. Some panels with the AUC of ≥0.9, the sensitivity of ≥80%, and the specificity of ≥80% are highlighted in dark green (**Figure [9](#F9){ref-type="fig"}**). For example, panel a exhibits excellent performance to differentiate male early stage lung cancer from male controls or male controls plus male benign lung diseases, along with the AUC of 0.95, the sensitivity of 83%, and the specificity of 90%, and panel l with the AUC of 0.90, the sensitivity of 90%, and the specificity of 77% has a good predictive ability to differentiate female early stage lung cancer from female controls or female controls plus female benign lung diseases. Representative ROC curves are shown in **Figure [10](#F10){ref-type="fig"}**.

Discussion
==========

In this study, the mixture of acetonitrile and methanol (3:2, v/v) was used to remove serum proteins [@B25], followed by phospholipids extraction with methylene chloride. Simultaneous quantitative analysis of six phospholipids was performed based on the CBDInanoESI-FTICR MS platform, and the levels of SM(34:1), PC(34:2), PC(34:1) PC(36:4), and PC(36:2) were calculated in term of their respective corresponding calibration equations (**Table [2](#T2){ref-type="table"}**), and PC(36:3) was calculated based on the calibration equation of PC(36:2). In addition, in order to reduce the intensities of adduct ions, such as \[M+Na\]^+^ and \[M+K\]^+^, which are generated in positive ion mode, 5 mM ammonium acetate solution was used to redissolve the dried samples prior to the CBDInanoESI-FTICR MS analysis [@B25], [@B26]. The quantitative method on the CBDInanoESI-FTICR MS platform demonstrated that the linearity, sensitivity, precision, and recovery are acceptable for complex biological sample analysis (**Table [2](#T2){ref-type="table"}**). The recoveries of phospholipids in both serum and the corresponding supernatant were almost identical (**Table [3](#T3){ref-type="table"}**). Therefore, in this study, we selected the addition of the internal standard (PC(36:0)) in supernatant instead of in serum to determine the levels of these six targeted phospholipids for enhancing the usage rate of serum samples.

Due to the gender-related differences in lipid metabolism [@B27]-[@B30] and the associations of incidence, mortality, survival rate, and prognosis of chronic diseases with gender [@B31]-[@B34], in this study, we have performed separate statistical analyses for males and females. Statistical results reveal that changes in the levels of these targeted phospholipids are significantly correlated with gender, pathophysiological states, types of cancers, and cancer stages. It should be noted that these six targeted phospholipids, specifically for SM(34:1), PC(34:2), and PC(34:1), were significantly up-regulated in lung, colorectal, and gastric cancer relative to pancreatic cancer, suggesting that these phospholipids metabolism may have different metabolic pathways for the diseases of different organs, which are consistent with previous studies [@B16]-[@B18]. Increased levels of PCs and SM may correlate with the overexpression of choline kinase in various cancers [@B35]-[@B37]. In addition, phospholipids are first synthesized via the Kennedy pathway followed by the remodeling pathway (Lands\' cycle). It should be noted that during this process, alterations in the expression of lysophospholipid acyltransferases, which play essential roles in regulating the synthesis of phospholipids [@B38], are closely correlated with cancers [@B39], [@B40].

For these four types of cancer, increased levels of the targeted phospholipids in lung, colorectal, and gastric cancer as well as their decreased levels in pancreatic cancer were observed, and these findings may be associated with the reduced generation of lipid hydroperoxides synthesized by phospholipid hydroperoxide glutathione peroxidase, which are in agreement with the decreased number of this enzyme in pancreatic cancer cell lines [@B41].

For lung diseases, the opposite trends in the levels of PC(34:2), PC(36:4), PC(36:3), and PC(36:2) between benign lung diseases and lung cancer relative to controls were detected (**Figure [2](#F2){ref-type="fig"}**). These results suggest that different metabolic pathways between these two pathological states may exist. For colorectal diseases and gastric diseases, increased trends of the levels of SM(34:1) PC(34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in male and female cancer patients were detected compared with the benign diseases patients with corresponding gender, except for SM(34:1) in the female gastric diseases. However, for pancreatic diseases, the opposite trends were detected in the males and females. Taken together, our findings indicate that different organs and different pathological states may have different phospholipids metabolisms and that phospholipids may be good organ-specific and pathology-specific biomarkers.

In addition, most potential biomarkers were obtained by comparison between cancer and normal controls [@B19], [@B42]-[@B44], and their clinical diagnosis performance are usually affected by some benign diseases. In this study, we not only compared the levels of six targeted phospholipids between controls, benign diseases, and corresponding cancer, but also between different diseases originated from four types of organ. Finally, ROC analysis revealed that 18 of panels of these six phospholipids have exhibited good performance to differentiate normal controls, benign diseases, cancers, early stage cancer, and late stage cancer. For example, panels a, b, and e have powerful diagnostic ability to differentiate different pathophysiological states, and panels a, b, d, e, h, l, and q have strong capacity to differentiate different cancer stages, with the AUC of ≥0.9, the sensitivity of ≥80%, and the specificity of ≥80%, which are better than CEA, Cyfra21-1, CA724, or CA19-9 [@B45]-[@B48].

Conclusions
===========

In this study, simultaneous quantification of SM(34:1), PC(34:2), PC(34:1) PC(36:4), PC(36:3), and PC(36:2) in 1449 serum samples was performed based on CBDInanoESI-FTICR MS. Our findings have revealed that significant differences in the levels of these six phospholipids between different pathophysiological states and between different cancer stages were observed after the gender classification. Different combinations of SM(34:1), PC(34:2), PC(34:1) PC(36:4), PC(36:3), and PC(36:2) have exhibited high diagnostic ability to differentiate different pathophysiological states and/or cancer stages.
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![Representative positive-ion mass spectra of the targeted phospholipids from one normal control (**A1**), one with benign lung disease (**A2**), with lung cancer (**A3**), benign colorectal disease (**B1**), colorectal cancer (**B2**), benign gastric disease (**C1**), gastric cancer (**C2**), benign pancreatic disease (**D1**), and pancreatic cancer (**D2**).](jcav08p2191g001){#F1}

![Scatter plots of serum levels of the targeted phospholipids for the training set, the validation set of lung diseases, as well as different stages of lung cancer. N, normal control; BLDs, benign lung diseases; LC, lung cancer; NC, non-lung cancers; ELC, early stage lung cancer (I or II); LLC, late stage lung cancer (III or IV). \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](jcav08p2191g002){#F2}

![Scatter plots of serum levels of the targeted phospholipids from patients with different colorectal diseases and different stages of colorectal cancer. N, normal control; BCDs, benign colorectal diseases; CRC, colorectal cancer; NC, non-cancers; ECRC, early stage colorectal cancer (I or II); LCRC, late stage colorectal cancer (III or IV). \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](jcav08p2191g003){#F3}

![Scatter plots of serum levels of the targeted phospholipids from patients with different gastric diseases and different stages of gastric cancer. N, normal control; BGDs, benign gastric diseases; GC, gastric cancer; NC, non-cancers; EGC, early stage gastric cancer (I or II); LGC, late stage gastric cancer (III or IV). \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](jcav08p2191g004){#F4}

![Scatter plots of serum levels of the targeted phospholipids from patients with different pancreatic diseases and different stages of pancreatic cancer. N, normal controls; BPDs, benign pancreatic diseases; PC, pancreatic cancer; NC, non-cancers; EPC, early stage pancreatic cancer (I or II); LPC, late stage pancreatic cancer (III or IV). \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](jcav08p2191g005){#F5}
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![Diagnostic performance of different panels for differentiating between normal controls (N), benign diseases (B), and cancers (C). NB for differentiating N from B; NC for differentiating N from C; BC for differentiating B from C; M, male; F, female. Strong predictive ability: AUC≥0.9, sensitivity≥80%, and specificity≥80%; weak predictive ability: AUC \< 0.9, or sensitivity \< 80%, or specificity \< 80%.](jcav08p2191g007){#F7}

![Representative ROC curves between normal controls (N), benign diseases, and cancers. (**A**) panel a for differentiating male normal controls from male patients with lung cancer. (**B**) panel b for differentiating female normal controls from female patients with lung cancer. (**C**) panel e for differentiating male patients with benign lung diseases from male patients with lung cancer. (**D**) panel e for differentiating male normal controls from male patients with gastric cancer. (**E**) panel e for differentiating female patients with benign gastric diseases from female patients with gastric cancer.](jcav08p2191g008){#F8}

![Diagnostic performance of different panels for differentiating normal controls (N), benign diseases (B), non-cancers (NC), early stage caner (E), and late stage cancer (L). NE for differentiating N from E; BE for differentiating B from E; NCE for differentiating NC from E; EL for differentiating E from L. Strong predictive ability: AUC≧0.9, sensitivity≧ 80%, and specificity≧80%; weak predictive ability: AUC \< 0.9, or sensitivity \< 80%, or specificity \< 80%. M, male; F, female](jcav08p2191g009){#F9}

![Representative ROC curves between normal controls (N), benign diseases, non-cancers (NC), early stage cancer (E), and late stage cancer (L). (**A**) panel a for differentiating male normal controls from male patients with early stage lung cancer. (**B**) panel a for differentiating male patients with non-cancers and male patients with early stage lung cancer. (**C**) panel a for differentiating male normal controls from male patients with early stage colorectal cancer. (**D**) panel b for differentiating female normal controls from female patients with early stage colorectal cancer. (**E**) panel d for differentiating female normal controls from female patients with early stage gastric cancer. (**F**) panel d for differentiating female patients with benign gastric diseases from patients with early stage gastric cancer. (**G**) panel e for differentiating male patients with benign lung diseases from male patients with early stage lung cancer. (**H**) panel e for differentiating female non-cancer patients from female patients with early stage gastric cancer. (**I**) panel h for differentiating female non-cancers patients from female patients with early stage colorectal cancer. (**J**) panel l for differentiating female normal controls from female patients with early stage lung cancer. (**K**) panel q for differentiating female patients with early stage gastric cancer from female patients with late stage gastric cancer.](jcav08p2191g010){#F10}

###### 

Demographic and clinical details of participants.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Health states               Training set\   Age\                              Validation set (male/female)   Age\
                              (male/female)   (years, mean ± SD, male/female)                                  (years, mean ± SD, male/female)
  --------------------------- --------------- --------------------------------- ------------------------------ ---------------------------------
                              354(282/72)                                       1095(562/533)                  

  **Normal controls**                                                                                          

  for lung                    177(141/36)     60 ± 11 / 59 ± 11                 69(27/42)                      60 ± 12 / 58 ± 12

  for colorectal                                                                144(66/78)                     62 ± 11 / 63 ± 10

  for gastric                                                                   94(65/29)                      62 ± 11 / 60 ± 13

  for pancreatic                                                                115(56/59)                     60 ± 13 / 55 ±15

  **Benign diseases**                                                                                          

  Lung                                                                          69(27/42)                      60 ± 12 / 58 ± 12

  Pneumonia                                                                     52                             

  Phthisis                                                                      1                              

  Nodule                                                                        7                              

  Embolism                                                                      1                              

  Interstitial lung disease                                                     8                              

  Colorectal                                                                    61(35/26)                      57 ± 12 / 56 ± 11

  Colitis                                                                       20                             

  Colonic polyps                                                                31                             

  Crohn\'s disease                                                              5                              

  Colonic ulcer                                                                 4                              

  Colopathy                                                                     1                              

  Gastric                                                                       54(38/16)                      60 ± 10 / 62 ± 11

  Gastritis                                                                     47                             

  Gastrohelcosis                                                                7                              

  Pancreatic                                                                    67(34/33)                      57 ± 13 / 53 ± 14

  Acute pancreatic                                                              13                             

  Chronic pancreatitis                                                          16                             

  Pancreatitis                                                                  28                             

  Pancreatic cyst                                                               10                             

  **Cancers**                                                                                                  

  Lung                        177(141/36)                                       69(27/42)                      60 ± 12 / 58 ± 12

  stage I or II               44(33/11)                                         12(3/9)                        

  stage III or IV             87(76/11)                                         41(14/27)                      

  Colorectal                                                                    144(66/78)                     62 ± 11 / 63 ± 9

  stage I or II                                                                 58(26/32)                      

  stage III or IV                                                               77(34/43)                      

  Gastric                                                                       94(65/29)                      63 ± 11 / 61 ± 13

  stage I or II                                                                 21(17/4)                       

  stage III or IV                                                               50(38/12)                      

  Pancreatic                                                                    115(56/59)                     60 ± 13 / 55 ±15

  stage I or II                                                                 16(8/8)                        

  stage III or IV                                                               48(19/29)                      
  ----------------------------------------------------------------------------------------------------------------------------------------------

###### 

The linearity range, calibration curve, correlation coefficient (R^2^), limit of detection (LOD), and recovery of phospholipids.

  Analytes                 Linearity (n=6)                                  Sensitivity          Precision (RSD%, n=9)          
  ---------- ------------- ------------------------------------ -------- -- ------------- ------ ----------------------- ------ -------
  SM(34:1)   0.32-166.06   y=0.2214(±0.0058)x+0.0115(±0.0047)   0.9998      0.16          0.32                           7.64   6.02
  PC(34:2)   1.13-578.02   y=1.4798(±0.0175)x-1.0047(±0.0633)   0.9919      0.14          1.13                           6.65   8.83
  PC(34:1)   0.45-230.59   y=1.0432(±0.0268)x-0.1846(±0.0365)   0.9934      0.06          0.45                           9.11   9.72
  PC(36:4)   0.55-280.14   y=0.4990(±0.0086)x+0.2291(±0.0225)   0.9814      0.07          0.55                           9.21   16.16
  PC(36:2)   0.59-300.99   y=0.9143(±0.0122)x-0.1201(±0.0211)   0.9993      0.07          0.59                           6.86   13.14

X: the concentration ratios of individual phospholipids to internal standard; Y: the respective corresponding intensity ratios of phospholipid to internal standard; RSD: relative standard deviation.

###### 

The recovery of the targeted phospholipids.

  Analytes   Recovery of added analytes (%, n=3)                                                                       
  ---------- ------------------------------------- -------------- ------- ------ ------------- -------------- -------- ------
  SM(34:1)   155.15                                110.77±7.86    71.39   7.10                 107.28±7.46    69.15    6.96
  51.24      33.61±4.06                            65.59          12.07          32.30±3.15    63.03          9.76     
  7.69       4.83±0.18                             62.8           3.82           5.07±0.30     65.93          5.92     
  PC(34:2)   330.00                                284.17±11.12   86.11   3.91                 280.07±15.66   84.87    5.59
  134.64     101.74±6.34                           75.56          6.23           101.02±3.26   75.03          3.23     
  47.52      36.07±1.12                            75.91          3.11           36.92±0.43    77.69          1.16     
  PC(34:1)   143.50                                117.20±3.51    81.67   3.00                 111.51±3.79    77.71    3.40
  95.84      73.11±3.56                            76.28          4.59           72.87±0.93    76.03          1.27     
  47.39      34.26±0.37                            72.29          1.09           36.94±2.37    77.93          6.42     
  PC(36:4)   139.46                                138.23±7.45    99.11   5.39                 141.66±4.27    101.57   3.01
  93.15      96.61±2.97                            103.43         3.08           105.34±4.63   112.78         4.40     
  46.06      51.95±0.83                            109.73         1.60           50.53±2.47    106.73         4.90     
  PC(36:2)   138.75                                107.89±2.40    77.76   2.23                 109.87±1.50    79.19    1.36
  92.67      77.24±1.40                            83.12          1.81           68.97±1.68    74.22          2.43     
  45.83      35.97±1.68                            78.50          4.67           36.71±1.84    80.10          5.02     

###### 

The AUC values, sensitivities, and specificities for differentiating normal controls (N), benign diseases (B), and cancer (C) based on different panels.

  Group            Sex   Panel   AUC   Sensitivity (%)     Specificity (%)   
  ---------------- ----- ------- ----- ------------------- ----------------- -------
  Training set                                                               
  Lung             NC    M       a     0.913(.884-.942)    83.6              83.6
                         F       b     0.938(.885-.990)    83.3              97.2
  Validation set                                                             
  Lung             NB    M       c     0.871(.778-.965)    81.5              81.5
                         F       d     0.900(.834-.966)    71.4              97.6
                   NC    M       a     0.960(.909-1.000)   92.6              96.3
                         F       b     0.949(.902-.996)    95.2              88.1
                   BC    M       e     0.929(.862-.995)    81.5              96.3
                         F       f     0.833(.750-.916)    81.0              71.4
  Colorectal       NB    M       g     0.841(.762-.920)    88.6              69.7
                         F       g     0.884(.801-.967)    80.8              88.5
                   NC    M       a     0.899(.846-.952)    77.3              92.4
                         F       h     0.899(.852-.946)    80.8              85.9
                   BC    M       a     0.774(.683-.865)    77.3              71.4
                         F       i     0.815(.727-.903)    73.1              80.8
  Gastric          NB    M       b     0.700(.598-.803)    81.6              55.4
                         F       j     0.873(.767-.979)    87.5              75.9
                   NC    M       e     0.952(.919-.984)    87.7              89.2
                         F       e     0.899(.852-.946)    80.8              85.9
                   BC    M       e     0.851(.779-.923)    70.8              89.5
                         F       e     0.925(.843-1.000)   86.2              100.0
  Pancreatic       NB    M       N/A   N/A                 N/A               N/A
                         F       N/A   N/A                 N/A               N/A
                   NC    M       g     0.898(.842-.954)    87.5              76.8
                         F       c     0.781(.698-.865)    83.1              62.7
                   BC    M       N/A   N/A                 N/A               N/A
                         F       k     0.672(.561-.784)    64.4              63.6

NB, between N and B; NC, between N and C; BC, between B and C; M, male; F, female.

###### 

The AUC values, sensitivities, and specificities for differentiating normal controls (N), benign diseases (B), non-cancers (NC), early stage cancers (E), and late stage cancers (L) based on different panels.

  Compared group   Sex   Panel   AUC   Sensitivity (%)      Specificity (%)   
  ---------------- ----- ------- ----- -------------------- ----------------- -------
  Lung             NE    M       a     0.968(.940-.996)     83.3              98.8
                         F       l     0.969(.934-1.000)    90.0              94.9
                   BE    M       e     0.961(.915-1.000)    86.1              100.0
                         F       m     0.807(.695-.919)     65.0              83.3
                   NCE   M       a     0.957(.926-.989)     88.9              90.8
                         F       l     0.903(.841-.966)     90.0              77.5
                   EL    M       N/A   N/A                  N/A               N/A
                         F       n     0.700(.568-.832)     44.2              95.0
  Colorectal       NE    M       a     0.917(.859-.976)     80.8              89.4
                         F       b     0.903(.841-.964)     81.3              87.2
                   BE    M       o     0.758(.634-.883)     80.8              65.7
                         F       i     0.822(.713-.932)     84.4              73.1
                   NCE   M       a     0.851(.773-.930)     73.1              87.1
                         F       h     0.902(.842-.962)     81.3              86.5
                   EL    M       N/A   N/A                  N/A               N/A
                         F       N/A   N/A                  N/A               N/A
  Gastric          NE    M       b     0.833(.717-.948)     76.5              83.1
                         F       d     1.000(1.000-1.000)   100.0             100.0
                   BE    M       o     0.740(.587-.893)     76.5              73.7
                         F       d     1.000(1.000-1.000)   100.0             100.0
                   NCE   M       b     0.801(.690-.913)     88.2              59.2
                         F       e     1.000(1.000-1.000)   100.0             100.0
                   EL    M       p     0.701(.552-.850)     78.9              64.7
                         F       q     1.000(1.000-1.000)   100.0             100.0
  Pancreatic       NE    M       a     0.833(.680-.985)     75.0              80.4
                         F       r     0.794(.687-.902)     100.0             71.2
                   BE    M       N/A   N/A                  N/A               N/A
                         F       N/A   N/A                  N/A               N/A
                   NCE   M       a     0.775(.629-.921)     75.0              73.3
                         F       N/A   N/A                  N/A               N/A
                   EL    M       N/A   N/A                  N/A               N/A
                         F       N/A   N/A                  N/A               N/A

NE, between N and E; BE, between B and E; NCE, between NC and E; EL, between E and L; M, male; F, female.
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